ArticleBMJ open2023

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).

Marie Reeberg Sass et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.